Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation ...

Results from pre-clinical studies conducted by scientists at Memorial Sloan Kettering Cancer Center show delayed leukemic progression and improved survival; Results from Phase 1 clinical trial in ...

Liquidia Corporation (LQDA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM ESTCompany ParticipantsRoger Jeffs - CEO ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and ...

NRx has refiled its Abbreviated New Drug Application for KETAFREE™ (preservative free ketamine), received supportive ...